The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,094.00
Bid: 12,094.00
Ask: 12,096.00
Change: 70.00 (0.58%)
Spread: 2.00 (0.017%)
Open: 11,950.00
High: 12,100.00
Low: 11,944.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Von der Leyen faces scrutiny over shaky EU vaccine strategy

Tue, 02nd Feb 2021 17:36

* EU under fire over slow vaccine rollout, border checks
issue

* Faces grilling at four EU lawmaker group meetings

* Von der Leyen says Commission has been 'quick on its feet'

* Sees easing of supply problems as production ramps up
(Adds EU lawmaker meetings, and comments by MEP, senior
diplomat)

By Philip Blenkinsop

BRUSSELS, Feb 2 (Reuters) - EU chief executive Ursula von
der Leyen on Tuesday faced hours of questioning by lawmakers
over the European Commission's vaccine strategy, focusing on a
slow roll-out and an export control plan that dismayed Britain
and Ireland.

Questions still surround the Commission's decision - swiftly
reversed - to invoke Article 16 of the Brexit agreement's
Northern Ireland protocol, a move that would have set up border
checks on the island of Ireland.

Von der Leyen, who has tweeted and appeared only on German
television since the bloc mandated authorisation for vaccine
exports, will be quizzed in meetings of three European
Parliament groupings on Tuesday evening and another on Wednesday
morning.

Sophie in 't Veld, a Dutch liberal lawmaker, said before her
group met that von der Leyen was relying on too narrow a circle
of advisers.

"She's made a couple of big fat mistakes. Article 16 was
one," she told Reuters, adding that her tendency to speak only
to German media was another problem.

A senior EU diplomat said von der Leyen's position was
probably safe with a closing of ranks around the Commission, but
there would be "some unpleasantness in coming days".

Senior British minister Michael Gove, who is to meet his
Commission counterpart on Wednesday, said London's trust in
Brussels had been eroded and that the two must resolve serious
problems over post-Brexit trade arrangements for Northern
Ireland.

REGRET OVER 'PROVISIONAL' DECISION

In interviews with newspapers outside Germany, the European
Commission president sought to defuse criticism over the EU's
slow start to COVID-19 vaccinations and outrage over the border
checks issue.

Asked by the Irish Times if she would apologise, von der
Leyen said she regretted that Article 16 was in a "provisional
version" of the decision, but said the EU executive had been
"quick on its feet" to find another solution.

In similar comments to France's Le Monde she said: "When you
take urgent decisions - in this year of crisis, the Commission
has taken almost 900 - there is always a risk of missing
something."

The vaccine crisis, which came to a head with EU export
controls announced on Friday, followed news that AstraZeneca
would cut its supply of vaccines to the bloc until March
by 60% due to production problems.

Even with the addition of an extra 9 million doses that von
der Leyen announced on Sunday, the shortfall is at least 50%.

EU countries have so far given first doses to about 3% of
their populations, compared with 9% for the United States and
14% for Britain, according to Our World in Data.

Von der Leyen said the supply problems should ease in the
second quarter of 2021, with more production capacity for
BioNTech/Pfizer and other potential approvals
of vaccines, including from Johnson & Johnson.

The Commission has ordered 2.3 billion doses from six
producers, far more than the bloc requires. Production, though,
was an enormous challenge, with clear teething problems.

"I see it as a marathon in which we have only covered the
first kilometres," she told Dutch newspaper De Volkskrant.
(Reporting by Philip Blenkinsop; additional reporting by John
Chalmers
Editing by Gareth Jones and Angus MacSwan)

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.